Abbott debuts Lingo over-the-counter CGM

Today’s Big News

Sep 5, 2024

Lykos CEO steps down, the latest move in a string of chaotic changes


Cash-crunched ImmunityBio, on heels of FDA nod for Anktiva, lays off staffers


Over-the-counter CGM market grows, with Abbott’s Lingo debut


AbbVie maintains grip on TV drug ad spending list as pharma digs deep in August


Eli Lilly jumps deeper into AI with $409M Genetic Leap deal


BioMarin outlines road map to $4B in sales by 2027 amid portfolio, organizational shake-ups

 

Featured

Lykos CEO steps down, the latest move in a string of chaotic changes

Lykos CEO and founder Amy Emerson is stepping down, with Chief Operating Officer Michael Mullette taking over the top spot on an interim basis.
 

Top Stories

Cash-crunched ImmunityBio, on heels of FDA nod for Anktiva, lays off staffers

The drugmaker laid off 20 employees as it attempts to recoup from dwindling funds during its Anktiva launch in bladder cancer.

Over-the-counter CGM market grows, with Abbott’s Lingo debut

The wellness-focused Lingo received the FDA’s blessing earlier this year, as one of the company’s first wearable blood sugar trackers to be offered without a prescription.

AbbVie maintains grip on TV drug ad spending list as pharma digs deep in August

It’s as you were at the top of the TV drug ad spending table as AbbVie continues its 2024 domination as total spending across the top 10 pharma companies rebounds from its summer lull.

Eli Lilly jumps deeper into AI with $409M Genetic Leap deal

Eli Lilly has vaulted into an AI-enabled drug discovery deal, partnering with RNA specialist Genetic Leap in a pact worth up to $409 million in upfront and milestone payments.

BioMarin outlines road map to $4B in sales by 2027 amid portfolio, organizational shake-ups

The company's game plan includes five new indications for dwarfism drug Voxzogo through 2031, which could represent a $5 billion opportunity covering a patient population of 420,000.

Lilly closes distance on Novo with another clutch of positive data on once-weekly insulin prospect

Early Thursday, Lilly unveiled positive topline results from a pair of phase 3 trials—QWINT-1 and QWINT-3—assessing its once-a-week basal insulin candidate called efsitora alfa. Both studies met their primary endpoints, with efsitora achieving non-inferior A1C reductions when pitted against two common daily insulins.

PAHO partners with Alzheimer’s Disease International on campaign to destigmatize dementia

In an attempt to stanch the flow of false beliefs about dementia, which may manifest as a lack of awareness about risk reduction options or poor treatment of those diagnosed with dementia, the United Nations’ Pan American Health Organization has launched a new campaign that’ll dole out information about the condition, its causes and its effects on everyday life.

Glenmark joins growing list of drugmakers to settle long-running US price-fixing claims

Glenmark will pay the U.S. Department of Justice $25 million to resolve claims that it worked with other drugmakers to rig prices of the cholesterol med pravastatin. The case forms part of a larger antitrust probe implicating numerous manufacturers.

Astellas unveils Massachusetts lab that will be shared with biotechs, academia researchers

Astellas Pharma has cut the ribbon on a new life sciences center in Massachusetts that will house 400 team members and an incubator lab.

WHO issues first guidance to address antibiotic pollution from drug manufacturers

After years of documentation and industry neglect, the World Health Organization issued its first-ever guidance aimed at addressing wastewater and solid waste from antibiotic manufacturers that is linked to antimicrobial resistance.

Crestone's antibiotic cures C. diff infections and prevents recurrence better than vancomycin in phase 2 study

The bacterium Clostridioides difficile is one of the most common infections picked up in hospitals, and, even once it’s cleared from the body, patients have a 1 in 6 chance of catching it again within a couple of months. It also often resists antibiotic treatment, leaving it free to infect the colon and cause diarrhea, nausea, fever and, in severe cases, sepsis and death.

BeiGene takes top sponsorship spot as Leukemia & Lymphoma Society campaign ramps up

The Leukemia & Lymphoma Society has marked National Blood Cancer Awareness Month with its 31st annual Light The Night campaign—and put its recently installed top pharma sponsor of the events in the spotlight.
 
Fierce podcasts

Don’t miss an episode

Driving flu vaccine uptake in the post pandemic era

In this week's episode of "The Top Line," we look at factors driving the continuing decline of flu vaccination rates in the U.S. and beyond.
 

Resources

Whitepaper

Building a “Best Practice” Commercial Organization in Biopharma

We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned.
Whitepaper

Epilepsy Clinical Trials

Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner.
 

Industry Events

On Helix

Date: ‌4 ‌July ‌2024 ‌- ‌Location: ‌Babraham ‌Research ‌Campus, ‌Cambridge ‌UK

 

Upcoming Fierce Events

9-12
Sep
Philadelphia, PA
11
Sep
Philadelphia, PA
17-19
Sep
Virtual Event
25-26
Sep
San Diego, CA
25-27
Sep
Philadelphia, PA

View all events